Gilead Sciences Inc. headquarters in Foster City, Calif., is seen Thursday, March 12, 2009. Biotechnology company Gilead Sciences Inc. said Thursday it will buy CV Therapeutics for about $1.4 billion as a wave of consolidation in the drug industry continues. (AP Photo/Paul Sakuma)
Gilead Sciences Inc. headquarters in Foster City, Calif., is seen Thursday, March 12, 2009. Biotechnology company Gilead Sciences Inc. said Thursday it will buy CV Therapeutics for about $1.4 billion as a wave of consolidation in the drug industry continues. (AP Photo/Paul Sakuma)
Gilead Sciences Inc. headquarters in Foster City, Calif., is seen Thursday, March 12, 2009. (AP Photo/Paul Sakuma)

However, hepatitis B infection is much more difficult to treat than hepatitis C.

READ MORE

Did you like this story?
Would you like to receive articles like this in your inbox? Free!

Leave a comment

Your email address will not be published. Required fields are marked *